Israel - Hebrew - Ministry of Health

novartis israel ltd - nepafenac - תרחיף לעין - nepafenac 0.1 % - nepafenac - nepafenac - prevention and treatment of postoperative pain and inflammation associated with cataract surgery and reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients.

Israel - Hebrew - Ministry of Health

novartis israel ltd - brinzolamide; timolol as maleate - תרחיף לעין - brinzolamide 10 mg/ml; timolol as maleate 5 mg/ml - timolol, combinations - timolol, combinations - decrease of intra-ocular pressure (iop) in adult patients with open-angle glaucoma or ocular hypertension for whom monotherapy provides insufficient iop reduction.

Israel - Hebrew - Ministry of Health

comex ltd - ivermectin 1.87 %w/w - oral paste - for the treatment and control of the following parasites of horses and donkeys:large strongyles: adults and arterial larval stages of strongylus vulgaris, adults and tissue larval stages of s. edentatus, adults of s. equinus and triodontophorus spp. adult and immature small stronyles influding benzimidazole resistant strains: cyathostomum spp, cylicocyclus spp, cyclicodontophorus spp, gyalocephalus spp. adult and immature lungworms: dictyocaulus arnfieldi. adult and immature oxxyuris equi. adult and immature parascaris equorum. adult trichostrongylus axei, habronema muscae and stronyloides westeri.microfilariae of onchocerca spp. oral and gastric stages of bots: gastrophilus spp.

Israel - Hebrew - Ministry of Health

linevitz eliezer - ivermectin 18.7 mg/g - paste - control the following horse parasites: large redworms: adult and arterial and 4-th larval ( arterial) stage of strongylus vulgaris adults and 4-th larval (tissue) stages of s. edentatus (adults) of s.eguinus. small redworm: adult and developing immatures (4-th stage larval) of the following species of small stronyles or cyathostomes: triodontophorus spp. (adults) coroncyclus spp. cyathostomum spp. cylococyclus spp. cylicostephanus spp. poteriostomum spp. (ivermectin is not effictive against encysted larval stages of the small strongyles.) pinworms: adult adn immature oxyuris equi. lungworms: adult and immature dictyocaulus arnfieldi. ascarids: adult and immature parascaris equorum. stomach worms: trichostrongylus axei and habronema muscae. intestinal threadworms: strongyloides westeri. cutaneous worms: microfilariae of onchocerca spp. bots: mouth and stomach stages of gasterophilus spp.

Israel - Hebrew - Ministry of Health

comex ltd - ivermectin - פסטה - פומי - ivermectin 1.87 %w/w

Israel - Hebrew - Ministry of Health

novartis israel ltd - brimonidine tartrate; brinzolamide - brimonidine tartrate 2 mg/ml; brinzolamide 10 mg/ml - brinzolamide, combinations

Israel - Hebrew - Ministry of Health

alexion pharma israel ltd - ravulizumab - תרכיז להכנת תמיסה לאינפוזיה - ravulizumab 10 mg/ml - ravulizumab

Israel - Hebrew - Ministry of Health

csl behring ltd., israel - anti-d immunoglobulins - תמיסה להזרקה - anti-d immunoglobulins 150 mcg/ml - anti-d (rh) immunoglobulin - anti-d (rh) immunoglobulin - prophylaxis of rh (d) immunisation in rh (d)-negative women: anti-d immune globulin is administered for the prevention of rh (d) immunization if it has been demonstrated or if it is suspected that fetal erythrocytes have entered the circulation of the mother. treatment is not necessary when it is assured that the child or the father are rh (d)- negative. criteria for a rhesus-incompatible pregnancy and the administration of anti-d immune globulin are : a) the mother is rh (d) -negative b) the child is either rh (d)-positive rh (d)weak - positive or its rhesus type is not known. routine antepartum prophylaxis : to prevent rh (d) immunisation due to spontaneous fetomaternal haemorrhage (fmh) during the last trimester of pregnancy. postpartum prophylaxis to prevent rh (d) immunisation of the rh (d)-negative mother following delivery of a rh (d)-positive child. complications of pregnancy: interventions during pregnancy such as invasive prenatal diagnosis (e.g. amniocentesis chorionic villus sampling fetal blood s

Israel - Hebrew - Ministry of Health

novartis pharma services ag - interferon beta 1b 0.3 mg - powder and solvent for solution for injection - interferon beta-1b - extavia is indicated for the treatment of:• for use in relapsing-remitting and relapsing-progressive multiple sclerosis. it is designated for ambulatory patients who meet criteria for clinically definite and for laboratory supported definite ms, and who have experienced at least two exacerbations over the last two years.extavia reduces the frequency of clinical exacerbations.in secondary progressive multiple sclerosis extavia is indicated for slowing progression of disease and for the reduction of frequency of clinical relapses. compared with placebo, patients receiving extavia showed a statistically significant delay in time to progression of multiple sclerosis. the treatment effect occurred in patients with and without relapses and at all levels of disability investigated (patients with mild disease and those unable to walk were not studied). patients receiving extavia also showed a statistically significant delay in the time to become wheelchair-bound when compared with placebo. see also section 5.1 “pharm

Israel - Hebrew - Ministry of Health

abbvie biopharmaceuticals ltd, israel - botulinum toxin type a - אבקה להכנת תמיסה לזריקה - botulinum toxin type a 100 u/vial - botulinum toxin - botulinum toxin - botox is indicated for the symptomatic relief of blepharospasm or vii nerve disorders in patients over 12 years hemifacial spasm and associated focal dystonias as well as the correction of strabismus in patients 12 years of age and above. botox is also indicated for the reduction of the signs and symptoms of spasmodic torticollis ( cervical dystonia) in adults. botox is also indicated for the treatment of dynamic equinus foot deformity due to spasticity in paediatric cerebral palsy patients two years of age or older. focal upper limb spasticity associated with stroke. botox is indicated also for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients aged 65 years or less. management of primary axillary hyperhidrosis in patients who failed other medical symptomatic treatment.symptom relief in adults fulfilling criteria for chronic migraine (headaches on ?15 days per month of which at least 8 days with migrai